antibody against the leukocyte VLA-4 (VCAM-1 ligand, natalizumab), slowed the progressive phase of MS. In particular, natalizumab was designed to block the immunocompetent T cell trafficking into the CNS; therefore, this drug was predicted to be the leading drug for MS as a BBB drug until its recall for clinical use after two patients with MS developed progressive multifocal leukoencephalopathy (PML) while being treated. The lessons from the natalizumab trials are that aggressive immunotherapy in MS to block T cell trafficking in the CNS, and by extension BBB modification, can be very risky. Immunotherapy in MS is yet to prove its value as a true cure for the disease. Reducing relapse is not necessary for an effective strategy to prevent serious and chronic disability in MS, based on recent epidemiological models 11, 12 . Anti-inflammatory therapy may only have a marginal therapeutic role in neurodegenerative diseases by limiting the secondary inflammation following primary myelin, axonal, and neuronal injury. What is currently lacking is neurodegeneration-focused research to identify the specific targets. There might be an intrinsic cause of tissue degeneration such as mitochondrial dysfunction 13 and glutamate excitotoxicity 14 in the initial MS pathogenesis. Now our major challenge for MS research is to elucidate and understand the real cause of MS. The study for the non-immune disease mechanisms and therapeutic options has been left unexplored; thus, we should move our research focus from the immunopathogenesis to neurodegenerative mechanisms to produce more creative approaches.
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journals.sagepub.com/home/msj S Bittner and F Zipp This month's issue of the Controversies series raises a fundamental question in neuroimmunology, namely, whether processes at the blood-brain barrier impact neurodegeneration. The blood-brain barrier forms a highly selective interface between the peripheral blood and brain compartment and can interact with infiltrating immune cells. [1] [2] [3] Extensive research efforts over the years have completely changed our view of the blood-brain barrier from a static, impermeable barrier to a dynamic, highly regulated, and specific cellular system. Most often, our focus lies on the inner layer of the blood-brain barrier, which consists of specialized brain microvascular endothelial cells. However, attached pericytes and astrocytic endfeet processes are also critically involved in induction, sustaining and regulating blood-brain barrier properties. Together with smooth-muscle cells, neurons, and circulating blood cells, they form the complex system of the so-called neurovascular unit. 4, 5 Already in the 1970s, links between vascular permeability and neurotoxicity were discussed. 6 But does studying the blood-brain barrier hold promises for a better understanding of neurodegenerative processes in MS? In this issue, Kamphuis and de Vries argue that changes in brain vascular function and inflammation are common in numerous neurological disorders but also in aging and memory loss. 7 Vascular dysfunction in the brain may even be a predisposition factor and pathways restoring impaired vascular function may provide means of fighting neurological diseases. The blood-brain barrier can therefore be seen as an active player protecting the brain against neurotoxic insult and promptly providing neurons with sufficient nutrients and oxygen. In fact, we discovered that endothelial cells themselves release extracellular matrix (ECM) components and that the ECM component epidermal growth factor-like protein 7 (EGFL7) regulates inflammation, thus limiting disease in the mouse model of MS. 8 Proper brain endothelial function is thus crucial for optimal neuronal activity and therefore exploring the behavior of the blood-brain barrier has, in fact, the potential to limit neurodegenerative processes.
In contrast, Tsutsui posits that while disruption of the blood-brain barrier is indeed a common hallmark of many chronic neurodegenerative disorders, it is still unclear whether this breakdown of the blood-brain barrier is an initial trigger leading to central nervous system (CNS) damage or instead an epiphenomenon of CNS inflammation, since inflammatory changes may only happen secondary to primary demyelinating or neurodegenerative events. Furthermore, current therapeutics aiming at modifying T cell trafficking into the CNS have-according to Tsutsui-failed to slow disease progression, underlining the need to investigate completely different processes underlying neurodegeneration instead of immune-mediated pathways in MS.
In our opinion, it is essential to focus on disease-specific changes in the blood-brain barrier as investigations may not yield the same results for classical and non-classical inflammation of the CNS (e.g. chronic neuroinflammation in MS vs primary neurodegenerative diseases), although certainly common features exist throughout chronic brain diseases, with the brain being a target of inflammatory processes. 9 It is clear that the blood-brain barrier is involved in the crosstalk of the immune and nervous systems and understanding its composition and functional regulation is of importance for therapeutic approaches in chronic diseases of the CNS. As of yet, we are far from understanding all the morphologic and functional peculiarities of this barrier which displays regional distinctions and has rendered novel transport concepts for several decades now. However, one important point might hold the key for addressing the most relevant future questions: the blood-brain barrier needs to be seen not as a passive barrier, but as a complex structure integrating and reacting to signals from the peripheral body and different cells within the brain parenchyma (astrocytes, neurons), overtaking even more complex functions than examined so far. Future investigations will also contribute to the development of novel biomarkers such as neurofilament light chain in the blood of patients reflecting both the function of the blood-brain barrier and neurodegenerative processes. 10, 11 New knowledge, for example, that intestinal microbiota control blood-brain barrier permeability, 12 keeps reshaping our view of this unique structure in our body. Neurodegeneration is only one of several pathologies in which we need to take into account the blood-brain barrier-but, moreover, other related barriers surrounding the brain, such as circumventricular organs, the blood-cerebrospinal fluid (CSF) barrier, and the barrier to lymphatic vessels, 13, 14 should also be explored.
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